• Veracyte’s third-quarter 2026 net income climbed 65% year-over-year to $31.5 million, while revenue rose 15% to $151.8 million.
• Operating income fell 28% year-over-year to $16.57 million.
• The board authorized up to $100 million in common stock repurchases; the business acquired bladder cancer testing developer Convergent Genomics.
• Full-year 2026 revenue guidance narrowed to $590 million–$593 million from $590 million–$596 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870413) on November 04, 2026, and is solely responsible for the information contained therein.